Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086908 | 0.81 | KDM4E (0.48) | ADRA1A | |
| SCHEMBL684805 | 0.81 | POLB (0.43) | KMT2APOLB | |
| SCHEMBL25863483 | 0.79 | ALDH1A1 (0.39) | KMT2AECE1 | |
| SCHEMBL17721379 | 0.77 | MEN1 (0.54) | CYP2C19KMT2AECE1 | |
| SCHEMBL18622102 | 0.77 | HDAC6 (0.32) | KMT2A | |
| SCHEMBL12672406 | 0.76 | HPGD (0.40) | CYP2C19KMT2AECE1 | |
| SCHEMBL19009425 | 0.76 | KMT2A (0.33) | KMT2A | |
| SCHEMBL20801342 | 0.76 | CASP2 (0.53) | KMT2A | |
| SCHEMBL21099918 | 0.76 | USP2 (0.50) | KMT2AECE1 | |
| SCHEMBL11960633 | 0.76 | ALOX15 (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-08-14 | — | — | US | disclosed |
| US-8680335-B2 | Processes of enantioselectively forming an aminoxy compound and an 1,2-oxazine compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-03-25 | — | — | US | disclosed |
| US-20110224429-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224429-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | AHR, CYP2S1, CYP1A1 | CYP2D6 112/4885CYP2C19 58/4885KMT2A 1871/4885 |
| US-20140228564-A1 | PROCESSES OF ENANTIOSELECTIVELY FORMING AN AMINOXY COMPOUND AND AN 1,2-OXAZINE COMPOUND | AHR, CYP2S1, CYP1A1 | CYP2D6 112/4885CYP2C19 58/4885KMT2A 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.